Analysts predict that Endologix, Inc. (NASDAQ:ELGX) will post $47.67 million in sales for the current quarter, Zacks reports. Four analysts have issued estimates for Endologix’s earnings, with estimates ranging from $47.50 million to $48.00 million. Endologix posted sales of $50.97 million during the same quarter last year, which suggests a negative year over year growth rate of 6.5%. The company is expected to report its next earnings results on Tuesday, August 1st.

According to Zacks, analysts expect that Endologix will report full-year sales of $47.67 million for the current year, with estimates ranging from $193.51 million to $196.40 million. For the next financial year, analysts expect that the firm will post sales of $209.49 million per share, with estimates ranging from $203.55 million to $216.30 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Endologix.

Endologix (NASDAQ:ELGX) last posted its quarterly earnings results on Thursday, May 4th. The medical instruments supplier reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.06. Endologix had a negative return on equity of 48.92% and a negative net margin of 66.43%. The business had revenue of $42.60 million during the quarter, compared to analysts’ expectations of $41.15 million. During the same quarter last year, the company posted ($0.25) earnings per share. Endologix’s quarterly revenue was up .5% on a year-over-year basis.

A number of research analysts have recently weighed in on the stock. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of Endologix in a research report on Wednesday, April 5th. Stifel Nicolaus reissued a “buy” rating and set a $5.50 target price (up from $5.00) on shares of Endologix in a research report on Monday, June 5th. Stephens downgraded shares of Endologix from an “overweight” rating to an “equal weight” rating and set a $6.00 target price for the company. in a research report on Thursday, May 18th. Royal Bank Of Canada reissued a “hold” rating and set a $8.00 target price on shares of Endologix in a research report on Thursday, April 13th. Finally, BMO Capital Markets reissued a “hold” rating and set a $7.00 target price on shares of Endologix in a research report on Tuesday, April 11th. Ten research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $7.52.

ILLEGAL ACTIVITY WARNING: “Brokerages Expect Endologix, Inc. (NASDAQ:ELGX) Will Announce Quarterly Sales of $47.67 Million” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/07/07/brokerages-expect-endologix-inc-nasdaqelgx-will-announce-quarterly-sales-of-47-67-million.html.

Endologix (NASDAQ ELGX) traded up 0.313% during trading on Friday, reaching $4.805. The company had a trading volume of 80,120 shares. The company’s market capitalization is $398.69 million. Endologix has a one year low of $4.21 and a one year high of $14.50. The company has a 50-day moving average price of $5.09 and a 200 day moving average price of $6.29.

In other Endologix news, Director Guido J. Neels acquired 20,000 shares of the business’s stock in a transaction that occurred on Friday, May 19th. The stock was bought at an average cost of $4.32 per share, with a total value of $86,400.00. Following the acquisition, the director now owns 61,380 shares in the company, valued at $265,161.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Dan Lemaitre acquired 22,522 shares of the business’s stock in a transaction that occurred on Monday, May 22nd. The stock was acquired at an average cost of $4.43 per share, with a total value of $99,772.46. Following the completion of the acquisition, the director now owns 68,689 shares in the company, valued at approximately $304,292.27. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 44,722 shares of company stock valued at $195,676. 3.90% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new position in Endologix during the first quarter valued at approximately $160,000. Menta Capital LLC acquired a new position in Endologix during the fourth quarter valued at approximately $132,000. Emerald Advisers Inc. PA acquired a new position in Endologix during the first quarter valued at approximately $222,000. Quantitative Systematic Strategies LLC acquired a new position in Endologix during the first quarter valued at approximately $261,000. Finally, MARSHALL WACE ASIA Ltd acquired a new position in Endologix during the first quarter valued at approximately $323,000.

Endologix Company Profile

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Get a free copy of the Zacks research report on Endologix (ELGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.